In vitro antitumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T-cell lymphomas

Journal of Immunotherapy

Volumn 30, Issue 2, 2007, Pages 190-202

  Troadec, Samuel ^a   Chentouf, Myriam ^a   Cérutti, Martine ^a   Nguyen, Brigitte ^a   Olive, Daniel ^b   Bès, Cédric ^a   Chardès, Thierry ^a  

^a CNRS   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Antibody; Baculovirus; CD4; CDR3 like loop; T lymphoma

Indexed keywords

BACULOVIRUS VECTOR; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT CD4 ANTIBODY 13B8.2; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; CD4+ T LYMPHOCYTE; CELL CYCLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CUTANEOUS T CELL LYMPHOMA; CYTOLYSIS; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHATIC LEUKEMIA; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD4; APOPTOSIS; BACULOVIRIDAE; CD4-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; COMPLEMENT C1Q; HUMANS; LYMPHOMA, T-CELL; MICE; RECEPTORS, IGG;

EID: 34247567055     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000211331.61019.26     Document Type: Article

References (64)

1. Krummel MF, Davis MM. Dynamics of the immunological synapse: finding, establishing and solidifying a connection. Curr Opin Immunol. 2002;14:66-74.
2. Veillette A, Abraham N, Caron L, et al. The lymphocyte-specific tyrosine protein kinase p56lck. Semin Immunol. 1991;3:143-152.
3. Querfeld C, Rosen ST, Guitart J, et al. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy. Curr Opin Hematol. 2005;12:273-278.
4. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5:664-672.
5. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol. 1999;26:74-78.
6. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66-73.
7. Dyer MJ. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol. 1999;26:52-57.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
9. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40.
10. Choy EH, Panayi GS, Emery P, et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal anti-body in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford). 2002;41:1142-1148.
11. Lopez E, Racadot E, Bataillard M, et al. Interferon gamma, IL2, IL4, IL10 and TNFalpha secretions in multiple sclerosis patients treated with an anti-CD4 monoclonal antibody. Autoimmunity. 1999;29:87-92.
12. Hayashi Y, Arakaki R, Ishimaru N. Apoptosis and estrogen deficiency in primary Sjogren syndrome. Curr Opin Rheumatol. 2004;16:522-526.
13. Gottlieb AB, Lebwohl M, Shirin S, et al. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study. J Am Acad Dermatol. 2000;43:595-604.
14. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation. 2004;77:990-997.
15. Vitova A, Filipec M, Zajicova A, et al. Prevention of corneal allograft rejection in a mouse model of high risk recipients. Br J Ophthalmol. 2004;88:1338-1342.
16. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis. 2004;189:286-291.
17. Reimann KA, Lin W, Bixler S, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses. 1997;13:933-943.
18. Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol. 2004;173:4715-4723.
19. Skov L, Kragballe K, Zachariae C, et al. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol. 2003;139:1433-1439.
20. Dhiver C, Olive D, Rousseau S, et al. Pilot phase I study using zidovudine in association with a 10-day course of anti-CD4 monoclonal antibody in seven AIDS patients. Aids. 1989;3:835-842.
21. Schedel I, Sutor GC, Hunsmann G, et al. Phase II study of anti-CD4 idiotype vaccination in HIV positive volunteers. Vaccine. 1999;17:1837-1845.
22. Troadec S, Bes C, Chentouf M, et al. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule. Clin Immunol. 2006;119:38-50.
23. Baldari CT, Milia E, Di Somma MM, et al. Distinct signaling properties identify functionally different CD4 epitopes. Eur J Immunol. 1995;25:1843-1850.
24. Pulito VL, Roberts VA, Adair JR, et al. Humanization and molecular modeling of the anti-CD4 monoclonal antibody, OKT4A. J Immunol. 1996;156:2840-2850.
25. Anderson D, Chambers K, Hanna N, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997;84:73-84.
26. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738-2743.
27. Benkirane M, Corbeau P, Housset V, et al. An antibody that binds the immunoglobulin CDR3-like region of the CD4 molecule inhibits provirus transcription in HIV-infected T cells. Embo J. 1993;12:4909-4921.
28. Jabado N, Le Deist F, Fisher A, et al. Interaction of HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human CD4+ T cells inhibits the binding activity of NF-AT, NF-kappa B and AP-1, three nuclear factors regulating interleukin-2 gene enhancer activity. Eur J Immunol. 1994;24:2646-2652.
29. Lemasson I, Briant L, Hague B, et al. An antibody that binds domain 1 of CD4 inhibits replication of HIV-1, but not HTLV-I, in a CD4-positive/p56lck- negative HTLV-I-transformed cell line. J Immunol. 1996;156:859-865.
30. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920-2924.
31. Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63:6453-6457.
32. Phillips KE, Herring B, Wilson LA, et al. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Cancer Res. 2000;60:6977-6984.
33. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64:2127-2133.
34. Knox SJ, Levy R, Hodgkinson S, et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood. 1991;77:20-30.
35. Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996;87:893-899.
36. Briant L, Devaux C. Bioactive CD4 ligands as pre- and/or postbinding inhibitors of HIV-1. Adv Pharmacol. 2000;48:373-407.
37. van Vugt MJ, Kleijmeer MJ, Keler T, et al. The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain. Blood. 1999;94:808-817.
38. Peltz GA, Trounstine ML, Moore KW. Cloned and expressed human Fc receptor for IgG mediates anti-CD3-dependent lymphoproliferation. J Immunol. 1988;141:1891-1896.
39. Vivier E, Rochet N, Ackerly M, et al. Signaling function of reconstituted CD16: zeta:gamma receptor complex isoforms. Int Immunol. 1992;4:1313-1323.
40. Poul MA, Cerutti M, Chaabihi H, et al. Cassette baculovirus vectors for the production of chimeric, humanized, or human antibodies in insect cells. Eur J Immunol. 1995;25:2005-2009.
41. Bes C, Briant-Longuet L, Cerutti M, et al. Mapping the paratope of anti-CD4 recombinant Fib 13B8.2 by combining parallel peptide synthesis and site-directed mutagenesis. J Biol Chem. 2003;278:14265-14273.
42. Gopal AK, Pagel JM, Hedin N, et al. Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. Blood. 2004;103:3516-3520.
43. Bezombes C, Grazide S, Garret C, et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 2004;104:1166-1173.
44. Benkirane M, Schmid-Antomarchi H, Littman DR, et al. The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4. J Virol. 1995;69:6904-6910.
45. Harding S, Lipp P, Alexander DR. A therapeutic CD4 monoclonal antibody inhibits TCR-zeta chain phosphorylation, zeta-associated protein of 70-kDa Tyr319 phosphorylation, and TCR internalization in primary human T cells. J Immunol. 2002;169:230-238.
46. Fehervari Z, Cooke A, Brett S, et al. Perturbation of naive TCR transgenic T cell functional responses and upstream activation events by anti-CD4 monoclonal antibodies. Eur J Immunol. 2002;32:333-340.
47. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383-3389.
48. Guillerm C, Robert-Hebmann V, Hibner U, et al. An anti-CD4 (CDR3-loop) monoclonal antibody inhibits human immunodeficiency virus type 1 envelope glycoprotein-induced apoptosis. Virology. 1998;248:254-263.
49. Sawitzki B, Lehmann M, Vogt K, et al. Bag-1 up-regulation in anti-CD4 mAb treated allo-activated T cells confers resistance to apoptosis. Eur J Immunol. 2002;32:800-809.
50. Choy EH, Kingsley GH. Anti-CD4 therapy in rheumatoid arthritis. Clin Exp Rheumatol. 1993;11(Suppl 8):S147-S149.
51. Milia E, Di Somma MM, Majolini MB, et al. Gene activating and proapoptotic potential are independent properties of different CD4 epitopes. Mol Immunol. 1997;34:287-296.
52. Fishman-Lobell J, Tsui P, Reddy M, et al. CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using Attractors. J Immunol Methods. 2001;257:71-82.
53. Oyaizu N, Adachi Y, Hashimoto F, et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J Immunol. 1997;158:2456-2463.
54. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology. 2002;107:176-182.
55. Janas E, Priest R, Wilde JI, et al. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139:439-446.
56. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. 1995;32:1311-1318.
57. Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005;23:567-575.
58. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466-3473.
59. Morgan A, Jones ND, Nesbitt AM, et al. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology. 1995;86:319-324.
60. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591-6604.
61. Umana P, Jean-Mairet J, Moudry R, et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17:176-180.
62. Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733-26740.
63. Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem. 1998;273:14008-14014.
64. Khoshnan A, Tindell C, Laux I, et al. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol. 2000;165:1743-1754.